ABSTRACT
In countries where CHD is prevalent, preventive strategies must aim,
on the one hand, to diminish the average level of risk in the general
population and, on the other, to target for more intensive intervention
those people who already have clinical CHD or are likely to acquire it
in the near future. The latter is the ‘high-risk’ or clinical approach for
which clinical trial evidence is strong. It is obviously a better option for
individuals at high-risk than reliance on population strategies.
